Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Protalix BioTherapeutics Inc’s stock clocked out at $2.52, down -6.32% from its previous closing price of $2.69. In other words, the price has decreased by -$6.32 from its previous closing price. On the day, 0.98 million shares were traded.
Ratios:
To gain a deeper understanding of PLX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.77 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 25.88. For the most recent quarter (mrq), Quick Ratio is recorded 1.27 and its Current Ratio is at 1.98. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 08, 2020, Reiterated its Buy rating but revised its target price to $11 from $3 previously.
On April 17, 2017, Rodman & Renshaw reiterated its Buy rating and also lowered its target price recommendation from $4 to $5.
On April 04, 2016, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $3.50.Rodman & Renshaw initiated its Buy rating on April 04, 2016, with a $3.50 target price.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 4.06 while its Price-to-Book (P/B) ratio in mrq is 5.72.
Stock Price History:
Over the past 52 weeks, PLX has reached a high of $2.76, while it has fallen to a 52-week low of $0.82. The 50-Day Moving Average of the stock is 17.17%, while the 200-Day Moving Average is calculated to be 80.08%.
Shares Statistics:
A total of 73.63M shares are outstanding, with a floating share count of 68.07M. Insiders hold about 7.56% of the company’s shares, while institutions hold 6.94% stake in the company.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0. Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
Revenue Estimates
In the current quarter, 2 analysts expect revenue to total $18.75M. It ranges from a high estimate of $19.29M to a low estimate of $18.21M. As of the current estimate, Protalix BioTherapeutics Inc’s year-ago sales were $10.49MFor the next quarter, 2 analysts are estimating revenue of $21.6M. There is a high estimate of $21.6M for the next quarter, whereas the lowest estimate is $21.6M.
A total of 2 analysts have provided revenue estimates for PLX’s current fiscal year. The highest revenue estimate was $54.47M, while the lowest revenue estimate was $53.39M, resulting in an average revenue estimate of $53.93M. In the same quarter a year ago, actual revenue was $65.49MBased on 2 analysts’ estimates, the company’s revenue will be $88.36M in the next fiscal year. The high estimate is $93.95M and the low estimate is $82.76M.
